prevnar 13 safety information important safety informationsevere allergic reaction eg anaphylaxis to any component of prevnar 13 ® or any diphtheria toxoid–containing vaccine is a contraindication immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response in adults the most commonly reported solicited adverse reactions were pain redness and swelling at the injection site limitation of arm movement fatigue headache muscle pain joint pain decreased appetite vomiting fever chills and rash indicationin adults 18 years of age and older prevnar 13 ® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by streptococcus pneumoniae serotypes 1 3 4 5 6a 6b 7f 9v 14 18c 19a 19f and 23flimitations of use and effectiveness prevnar 13 ® will only help protect against s pneumoniae serotypes in the vaccine patients should always ask their doctors for medical advice about adverse events you are encouraged to report negative side effects of vaccines to the us food and drug administration fda and the centers for disease control and prevention cdc visit wwwvaershhsgov or call 18008227967 this website is neither owned nor controlled by pfizer pfizer does not endorse and is not responsible for the content or services of this site please see full prescribing information for prevnar 13 ® clinical information administration cdcs acip adult recommendations for prevnar 13®immunogenicity and safety proven efficacy and safety risk factors support  services medicare coverage and reimbursement nurse resources ordering vaccines and customer service pharmacist resources physician resources shot or not game test your knowledge of the cdc’s acip pneumococcal vaccination recommendations for adults aged 65 and older click to play shot or notphysician resources additional tools to help integrate prevnar 13 ® into your practice download now nurse resources materials to help educate patients about prevnar 13 ® vaccination and to assist you with billing and coding download now pharmacist resources additional tools to help identify appropriate patients and to ensure uptodate vaccination records download now learn about the cdcs acip adult recommendations for prevnar 13 ®learn more landmark trial capi tacommunityacquired pneumonia immunization trial in adults one of the largest prospective adult vaccine trials ever conducted 2view results coverage  reimbursement prevnar 13 ® is covered by the medicare part b feeforservice ffs benefit for adults aged 65 and older with 0 in outofpocket costs learn more scroll for important safety information and indication important safety informationsevere allergic reaction eg anaphylaxis to any component of prevnar 13 ® or any diphtheria toxoid–containing vaccine is a contraindication immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response in adults the most commonly reported solicited adverse reactions were pain redness and swelling at the injection site limitation of arm movement fatigue headache muscle pain joint pain decreased appetite vomiting fever chills and rash indicationin adults 18 years of age and older prevnar 13 ® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by streptococcus pneumoniae serotypes 1 3 4 5 6a 6b 7f 9v 14 18c 19a 19f and 23flimitations of use and effectiveness prevnar 13 ® will only help protect against s pneumoniae serotypes in the vaccine patients should always ask their doctors for medical advice about adverse events you are encouraged to report negative side effects of vaccines to the us food and drug administration fda and the centers for disease control and prevention cdc visit wwwvaershhsgov or call 18008227967 this website is neither owned nor controlled by pfizer pfizer does not endorse and is not responsible for the content or services of this site please see full prescribing information for prevnar 13 ® manufactured by wyeth pharmaceuticals inc © 2018 pfizer inc all rights reserved marketed by pfizer inc january 2018